IN8bio (INAB)

IN8bio (INAB) Stock Price & Analysis


INAB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.02 - $3.95
Previous Close$3.15
Average Volume (3M)3.73M
Market Cap
Enterprise Value$88.34M
Total Cash (Recent Filing)$10.90M
Total Debt (Recent Filing)$5.53M
Price to Earnings (P/E)-2.3
Sep 08, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding29,750,348
10 Day Avg. Volume365,075
30 Day Avg. Volume3,731,207
Standard Deviation0.31
Financial Highlights & Ratios
Price to Book (P/B)13.32
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.09
Price Target Upside315.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was $1.02 and its highest was $3.95 in the past 12 months.
    What is IN8bio’s market cap?
    Currently, no data Available
    When is IN8bio’s upcoming earnings report date?
    IN8bio’s upcoming earnings report date is Sep 08, 2023 which is in 95 days.
      How were IN8bio’s earnings last quarter?
      IN8bio released its earnings results on May 12, 2023. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.02.
        Is IN8bio overvalued?
        According to Wall Street analysts IN8bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does IN8bio pay dividends?
          IN8bio does not currently pay dividends.
          What is IN8bio’s EPS estimate?
          IN8bio’s EPS estimate is -$0.27.
            How many shares outstanding does IN8bio have?
            IN8bio has 29,750,347 shares outstanding.
              What happened to IN8bio’s price movement after its last earnings report?
              IN8bio reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went up 7.798%.
                Which hedge fund is a major shareholder of IN8bio?
                Currently, no hedge funds are holding shares in INAB


                IN8bio Stock Smart Score

                The IN8bio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description


                IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.


                Top 5 ETFs holding INAB

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold INAB. The ETFs are listed according to market value of INAB within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                X4 Pharmaceuticals
                Genfit SA
                Vascular Biogenics
                Bioxcel Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis